Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 1, 2021

WuXi Biologics – Global Solution Provider

WuXi Biologics, a Hong Kong-listed company (2269.HK), is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics and vaccines from concept to commercial manufacturing. We offer a true one-stop CDMO offering from DNA to IND and a premier-quality manufacturing global supply chain network across four countries.

WuXi Biologics
108 Meiliang Road. W,
MaShan Binhu District,
Jiangsu Province
Wuxi 214092, China
Tel.+86 (510).8183.1200
info@wuxibiologics.com www.wuxibiologics.com


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.